Hematology Phase 3 Deal Benchmarks — Ex-US

Understanding Hematology Deal Benchmarks at Phase 3

Phase 3 Hematology licensing deals in Ex-US territory command a median upfront payment of $907M, with values ranging from $577M at the low end to $1.3B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the hematology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.3B to $3.9B, with a median of $3.1B. Royalty rates for hematology assets at this stage typically fall between 9.3% and 16.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.